Dekabank Deutsche Girozentrale Reduces $1M in Agios Pharmaceuticals, Inc. ($AGIO)
Key Points
- Dekabank Deutsche Girozentrale changed its Agios Pharmaceuticals, Inc. ($AGIO) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $AGIO is Buy and an average price target of $40.25.
- $AGIO last traded around $28.72.
Dekabank Deutsche Girozentrale reduced its position in Agios Pharmaceuticals, Inc. ($AGIO), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Agios Pharmaceuticals, Inc. after selling 40,000 shares during the quarter.
Agios Pharmaceuticals, Inc. ($AGIO) Stock
Agios Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.